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Abstract
The myxobacterial strain Stigmatella aurantiaca MYX-030 was selected as promising source for the discovery of new biologically
active natural products by our screening methodology. The isolation, structure elucidation and initial biological evaluation of the
myxocoumarins derived from this strain are described in this work. These compounds comprise an unusual structural framework
and exhibit remarkable antifungal properties.
Introduction
Despite declining interest of most big R&D-driven chemical
companies in recent years, natural products continue to serve as
one of the most important sources of new bioactive chemical
entities, both in the pharmaceutical [1-4] as well as in the agro-
chemical industry [5-8]. A particularly rich source of intriguing
secondary metabolites with interesting biological properties are
the myxobacteria [9-12]. These organisms are especially
talented in assembling PKS-, NRPS- and PKS/NRPS-hybrid
products, often incorporating unusual biochemistry in the
respective biosynthetic pathways [13-15]. The most well-known
myxobacterial natural products are the epothilones (e.g.
epothilones A (1), Figure 1), microtubule-stabilizing macrolac-
tones that are clinically used in cancer therapy [16-20].
But also from an agrochemical point of view, myxobacteria
have already furnished a large set of promising lead structures,
in particular in the context of antifungal compounds with
around 50% of myxobacteria-derived natural products exhibit-
ing such properties [10]. This activity of myxobacterial metabo-
lites results from diverse modes of action, such as inhibition of
DNA replication, transcription and translation, as well as inter-
ference with cell membrane stability [21]. Inhibition of acetyl-
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Figure 1: Structures of epothilone A (1), soraphen A1α (2), pyrrolnitrin (3), fenpiclonil (4), myxothiazol A (5), and aurachin A (6).
CoA carboxylase is exerted by soraphen A1α (2), which has
been shown to be a potent and broad spectrum fungicide
[22,23]. The most dominant target of myxobacterial antifungal
agents, however, is the mitochondrial respiratory chain [21].
The compounds thereby either target complex I (NADH dehy-
drogenase) of the electron transport chain, as for example
pyrrolnitrin (3) [24,25], which is in use for the treatment of
fungal skin infections [26] and served as a lead structure for the
development of the agrochemical agents fenpiclonil (4) and
fludioxonil [27], or complex III (cytochrome bc1), as for
example myxothiazol A (5) [28,29]. Compounds of the same
structural family can also target different target complexes
simultaneously, as for example in the case of aurachins (e.g.
aurachin A (6), Figure 1) [30-32]. Due to the remarkably high
percentage of antifungal myxobacterial natural products, we
investigated the potential of new myxobacterial isolates towards
the production of novel, agrochemically relevant antifungal lead
structures. The results obtained with strain Stigmatella
aurantiaca MYX-030 are described herein.
Results and Discussion
The myxobacterial strain Stigmatella aurantiaca MYX-030 has
been selected as interesting producer of bioactive natural prod-
ucts by our standardized hit follow-up process. Initial dereplica-
tion of known compounds was performed by using
HPLC–UV–MS [33] combined with Peak–Activity–Correla-
tion (PAC) data. Taken together these results indicated the pres-
ence of the known antifungal myxobacterial compound
myxothiazole A (5), as well as the aurachins A (6) and C in the
extract. In addition to these metabolites, a series of non-polar
compounds exhibiting strong antifungal activity was detected.
Comparison of UV and molecular mass data of these secondary
metabolites with an in-house compound library resulted in no
hits, thus prompting us to their isolation and structural elucida-
tion.
The UV spectrum of 7 revealed maxima at 218 and 286 nm,
strongly suggesting the presence of an aromatic system within
the structure. Negative mode ESIMS analysis of the most abun-
dant congener 7 of this set of natural products showed strong
signals at 378.2 ([M − H]−) and 757.4 ([2M − H]−) as well as a
positive ESIMS signal at 362.2 ([M − H2O + H]
+). High resolu-
tion positive mode ESI–TOF mass analysis resulted in a molec-
ular mass of 380.2097 u, which best fits a calculated molecular
formula of C20H30NO6 for the [M + H]
+ ion of 7, thus indi-
cating 7 degrees of unsaturation. The calculated number of
carbon atoms was further substantiated by the 20 resolved
signals observed in the compound’s 13C NMR spectrum
(Table 1). These signals were assigned to three methyl groups
(14.0, 16.5, and 21.2 ppm), eight methylene units (22.6, 23.4,
29.2, 29.3, 29.4, 29.8, 31.8, and 38.3 ppm), a quaternary carbon
at 46.5 ppm, a heteroatom-substituted quaternary carbon – most
likely a tertiary alcohol – at 79.1 ppm, an ester-type function-
ality at 172.5 ppm, and six sp2-hybridized carbon atoms as part
of an highly heteroatom-substituted aromatic system (103.2,
108.0, 118.6, 148.3, 149.2, and 157.8 ppm). The presence of the
latter moiety was further corroborated by the 1H NMR spectral
data: two doublets with chemical shifts at 7.43 and 7.35 ppm
and a coupling constant of 2 Hz clearly evidenced a highly
substituted aromatic ring system bearing two protons in meta-
position to each other.
The proton signals at 7.43 and 7.35 ppm correlated in an HSQC
experiment with the 13C NMR signals at 108.0 and 103.2 ppm,
respectively. The structural organization of the aromatic system
was further investigated by HMBC spectroscopy. The proton at
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Figure 2: HMBC interactions used for the structure elucidation of myxocoumarin A (7).
Table 1: NMR data of compound 7 at 500 (1H) and 150 (13C) MHz.







6 108.0, CH 7.43, d (2) 4’, 5, 7, 8
7 148.3, C
8 103.2, CH 7.35, d (2) 4’, 7, 8’
8’ 149.2, C
9 38.3, CH2 1.56, td
1.99, td
3, 4, 4’, 10,
11
3, 4, 4’, 10,
11
10 23.4, CH2 1.49, m
1.08, m
11 29.2*, CH2 1.14-1.30, m
12 29.3*, CH2 1.14-1.30, m
13 29.4*, CH2 1.14-1.30, m
14 29.8*, CH2 1.14-1.30, m
15 31.8, CH2 1.14-1.30, m
16 22.6, CH2 1.14-1.30, m
17 14.0, CH3 0.86, t (7) 15, 16
18 16.5, CH3 1.33, s 2, 3, 4, 19
19 21.2, CH3 1.18, s 2, 3, 4, 18
aRecorded in CDCl3 containing a drop of CD3OD; b1H, HSQC and
HMBC data recorded in CD3OD. *Signal assignment interchangeable.
7.43 ppm showed strong correlations with two of the
heteroatom-substituted carbons at 157.8 and 148.3 ppm, the
putatively alkyl substituted position at 118.6 ppm, as well as the
C atom at 103.2 ppm. The proton at 7.35 ppm, in turn, corre-
lated with the C atoms at 149.2, 148.3, and 118.6 ppm, leading
to overall structural fragment I (F-I) shown in Figure 2. In addi-
tion to the aromatic protons, three methyl signals were observed
in the 1H NMR spectra: a triplet at 0.86 ppm (3J = 7 Hz),
suggesting a methyl group directly attached to a CH2-unit, as
well as two singlets at 1.18 and 1.33 ppm. Furthermore, a pair
of diastereomeric protons at 1.56 and 1.99 (higher order multi-
plets with a triplet of doublets structure) and a set of diastere-
omeric protons at 1.08 and 1.49 ppm (m) were observed. The
signals of the other six methylene units formed a multiplet at
1.14–1.30 ppm, indicating the presence of a linear alkyl chain in
the molecule. This is corroborated by the HSQC correlations to
the C atoms at 29 ppm, as well as 22.6 and 31.8 ppm. In the
HMBC data, strong correlations of the isolated methyl groups to
each other, to the putative ester functionality, the quaternary
carbon at 46.5 ppm, and the tertiary alcohol carbon at 79.1 ppm
led to the assembly of structural fragment II (F-II, Figure 2).
Further substitution of the latter was obvious from HMBC cross
peaks of the diastereotopic CH2 group (1.56 and 1.99 ppm) to
the latter position (79.1 ppm) and to the carbon bearing the two
methyl groups (46.5 ppm), as well as to the aromatic carbon at
118.6 ppm. In addition, this methylene unit exhibited correla-
tions with two further CH2 groups of the linear alkyl chain. This
side chain turned out to consist of 8 neighboring CH2 units with
the methyl functionality at 0.86 ppm as the end group, as
evident from HMBC correlations of the latter to the final two
methylene units of this chain (F-III, Figure 2). Taken together,
this information allowed the assembly of all aforementioned
structural fragments to give a draft structure 8. Given the chem-
ical shifts of the carbonyl C-2 (172.5 ppm) and of carbon C-8’
(149.2 ppm), the presence of a lactone moiety can be deduced.
The resulting overall structure still lacks three oxygens, a
hydrogen, and a nitrogen atom combined with one degree of
unsaturation when compared to the calculated molecular
formula of 7. Consequently, the substituents at C-5 and C-7 can
be identified as an OH and a nitro function, respectively, as also
indicated by the chemical shifts of C-5 (157.8 ppm) and C-7
(148.3 ppm). This results in the final overall structure 7 of this
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natural product. To unambiguously prove the substitution
pattern at the aromatic ring system, the phenolic OH-group was
selectively methylated using diazomethane. The resulting
methyl ether was irradiated in a 1D NOE experiment, which
resulted in the expected strong increase of the proton bound to
C-6. This observation thus firmly validated that the methyl ether
had to be situated at C-5, as its alternative location at C-7 would
have led to a strong increase in signal intensity of the protons
bound to both, C-6 and C-7.
Owing to its coumarin core structure and its biological origin,
compound 7 was named myxocoumarin A (7). Besides 7, a
second metabolite 9 with a highly similar NMR spectrum was
isolated. ESIMS analysis of 9 showed a molecular ion peak at
346.2 ([M − H]−, negative mode) and 348.2 ([M + H]+, posi-
tive mode), consistent with a formal loss of MeOH when
compared to the molecular mass of myxocoumarin A (7). In ad-
dition, no loss of water was observable in the MS data,
suggesting the hydroxy function at C-4 in 7 not to be present in
9. Comparison of the 1H NMR spectra of 7 and 9 furthermore
revealed the missing signals of the methyl groups 18 and 19 of
7 in the spectrum of 9, along with a new singlet at 2.20 ppm
integrating for three protons. In conclusion, this lead to the
proposed structure of myxocoumarin B (9) as shown in
Figure 3, which was unambiguously verified by in-depth
analysis of chemical shifts in comparison with literature data
(see Supporting Information File 1).
Figure 3: Chemical structure of myxocoumarin B (9).
Unfortunately, the amount of 7 isolated from the initial fermen-
tation broth was not sufficient for stereochemical investigations,
nor did the obtained amount of 9 suffice to obtain high quality
13C NMR data. Attempts to produce more crude material were
not successful, as cryo cultures of the producing strain failed to
be transformed into actively growing cultures again.
Coumarins in general constitute a large group of bioactive
natural products, mostly isolated from plants. Most of these
plant-derived compounds are polyphenols that are often further
modified by most diverse functionalization reactions, such as
O-methylation, glycosylation, prenylation, oxygenation and
subsequent cyclization or dimerization events [34]. Nitrogen-
bearing congeners are rather scarce, with the bacterial
aminocoumarins, such as the gyrase inhibitor novobiocin, being
the most well-known examples [35]. Despite the larger number
of existing coumarin structures in literature, the 5-hydroxy-7-
nitro substitution pattern combined with the unusual long-chain,
fully saturated alkyl substituent at C-4 are unique to the
myxcoumarins 7 and 9.
With the production of myxothiazol A (5) and aurachin A (6),
the investigated strain Stigmatella aurantiaca MYX-030 resem-
bles the secondary metabolite profile of previously chemically
investigted S. aurantiaca and S. erecta strains. Interestingly,
both, S. aurantiaca Sg a15 and S. erecta Pd e21, were reported
to produce 5-nitroresorcinol (13) [36]. The biosynthesis of 13
was investigated in S. erecta Pd e21 using isotope-labeling
experiments that revealed its precursor molecules to be glucose-
derived erythrose-4-phosphate (10) and phosphoenol-pyruvate
(11, Scheme 1). Due to the observed scrambling of the expected
labeling pattern in 13, its biosynthesis has to proceed via a
symmetrical intermediate, putatively phloroglucinol (12) [36].
Nitrophenol 13 likely constitutes a direct biosynthetic precursor
of the myxocoumarins. Upon O-acetylation of 13 with the long-
chain β-keto acid building block 14, putatively recruited from
fatty-acid biosynthesis, the intermediate ester 15 could undergo
C–C bond formation by nucleophilic attack of the aromatic
system to the side-chain keto functionality, comparable to the
first step of a Pechman condensation reaction. This would
already furnish mycoxoumarin A (7, R2 = Me), with myxo-
coumarin B (9, for R2 = H) being formed after additional loss of
H2O. In order to identify further myxocoumarin producing
strains, chemical screenings of the secondary metabolite
profiles of S. aurantiaca Sg a15 and S. erecta Pd e21 using the
fermentation conditions identified for S. aurantiaca MYX-030
might thus be worthwhile.
To verify the initially measured antifungal activity from the
PAC, myxocoumarin A (7) was subjected to leaf disk assays
against a series of agriculturally relevant pathogenic fungi. The
compound revealed interesting antifungal activities with
complete inhibition of agronomically important pathogens such
as Botrytis cinerea at 200 mg/L as well as Magnaporthe grisea
and Phaeosphaeria nodorum at 67 mg/L. Partial effects were
found against Blumeria graminis (67 mg/L). The compound
was, however, inactive against Drechslera teres and Phytoph-
thora infestans. These findings indicate a broad range anti-
fungal activity of 7, comparable to commercial standard fungi-
cides, although on a somewhat lower activity level. To further
substantiate these results, liquid culture assays against a set of
fungal pathogens were performed, showing strong intrinsic anti-
fungal activities against M. grisea (100% inhibition at
0.7 mg/L) as well as B. cinerea, Fusarium culmorum, and P.
nodorum (all at 2 mg/L), with no activity against Pythium
Beilstein J. Org. Chem. 2013, 9, 2579–2585.
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Scheme 1: Postulated biosynthetic pathway to myxocoumarins A (7) and B (9).
ultimum and Rhizoctonia solani. So far, no insecticidal and
herbicidal activities have been observed. Due to the problems
arising from the lacking culturability of the producing strain S.
aurantiaca, further tests with 7 were so far not possible. Struc-
ture–activity relationship (SAR) studies on synthetic myxo-
coumarin derivatives as well as in-depth investigation of their
antibacterial potential are currently performed in our laboratory
and will be reported in due course.
Experimental
Cultivation and extraction. The preculture of S. aurantiaca
MYX-030, inoculated directly from a single culture of an agar
plate, was incubated by shaking (150 rpm) at 30 °C for 7 days
in a 500 mL shake flask without baffle containing 80 mL of
medium MIX-5 (composition: 2 g glucose, 5 g potato starch,
2 g peptone, 0.5 g MgSO4, 0.5 g CaCl2, 10 g HEPES for 1 L
H2O, pH 7.4). For production of myxocoumarins, 3 × 200 mL
production cultures in 500 mL flasks without baffle were inocu-
lated with 20 mL of the preculture. Production was carried out
by shaking (150 rpm) at 30 °C for 10 days in MIX-1 media
(composition: 5 g casitone, 2 g starch, 2 g MgSO4, 0.5 g CaCl2,
1 mL mineral solution (consisting of 0.1 g H3BO3, 5 g
FeSO4·7H2O, 0.05 g KI, 2 g CoCl2·6H2O, 0.2 g CuSO4·5H2O,
2 g MnCl2·4H2O, 4 g ZnSO4·7H2O, 1 g 95% H2SO4 for 1 L
solution), 10 mL vitamin solution (consisting of 10 mg folic
acid, 6 mg biotin, 0.2 g p-aminobenzoic acid, 1 g thiamin·HCl,
1.2 g panthothenic acid, 1 g riboflavin, 2.3 g nicotinic acid,
1.2 g pyridoxine·HCl, 0.1 g vitamin B12 for 1 L solution) for
1 L H2O, pH 7.4) supplemented with 10% XAD-16 for
continued product absorption during fermentation. Cells and
XAD-16 were separated from the culture broth by filtration and
subsequently extracted using methanol and acetone.
Isolation of mycoxoumarins A (7) and B (9). The crude ma-
terial obtained by extraction of bacterial cells and XAD
(341 mg) was subjected to chromatography on Sephadex LH-20
(3 × 69 cm column, flow: 1.6 mL/min) using methanol as the
eluent. The myxocoumarin containing fraction (12.1 mg) was
purified by reversed-phase preparative HPLC (Bischoff
Kromasil 100 C-18, 10 µm, 2 cm diameter, 20 cm length) using
H2O + 0.1% TFA (solvent A) and acetonitrile (ACN) + 0.1%
TFA (solvent B) as the eluents at a flow rate of 10 mL/min
using the following linear gradient: 0 min 80% A, 2 min 80%
A, 20 min 50% A, 25 min 20% A. Myxocoumarin A (7) was
collected at a retention time of 12.5 min and myxocoumarin B
(9) at 14.7 min to give 1.9 mg and 0.5 mg pure material, res-
pectively.
Myxocoumarin A (7): pale yellow solid, [α]D
 20 −6.3 (c 0.2,
methanol); 1H and 13C NMR data, see Table 1; UV (H2O
(64%)/ACN (36%) + 0.1% TFA, online) λmax, nm: 218, 286,
340 (sh); ESIMS(−) m/z: 57.4 [2M − H]−, 378.2 [M − H]−;
ESIMS(+) m/z 362.2 [M − H2O + H]
+; HRMS–ESI(+) m/z:
[M + H]+ calcd. for C20H30NO6, 380.207; found, 380.2097
(calculated for).
Myxocoumarin B (9): pale yellow solid, 1H NMR (500 MHz,
CD3OD) δH 7.55 (d, J = 2 Hz, 1H, H-6), 7.51 (d, J = 2 Hz, 1H,
H-8), 3.18 (m, 2H, H-9), 2.20 (s, 3H, H-18), 1.62 (m, 2H,
H-10), 1.49 (m, 2H, H-11), 1.42–1.26 (m, 10H, H-12, H-13,
Beilstein J. Org. Chem. 2013, 9, 2579–2585.
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H-14, H-15, H-16), 0.90 (t, J = 7 Hz, 3H, H-17); UV (H2O
(61%)/ACN (39%) + 0.1% TFA, online) λmax, nm: 233, 260,
332 (sh); ESIMS(−) m/z: 693.3 [2M − H]−, 346.2 [M − H]−;
ESIMS(+) m/z: 348.2 [M + H]+.
Biological testing. Cut leaf disks (15 mm2) of the respective
host plants (see below) were placed on water agar in multi-well
plates (24-well format) and sprayed with 12 µL aqueous test
solution of varying concentrations (dose range 22–200 mg/L)
using automated microspray technology. After drying, the leaf
disks were inoculated with a spore suspension of the respective
pathogenic fungus (see below). The activity of myxocoumarin
A (7) was assessed 4–6 days after inoculation as percent
preventive antifungal activity as compared to the non-treated
controls. The following host/pathogen combinations were used:
Phytophthora infestans (Mont) de Bary (late blight) on tomato;
Botrytis cinerea Pers.: Fr. (gray mould) on bean; Blumeria
graminis f.sp. hordei (DC.) Speer (powdery mildew) on barley;
Drechslera teres (Sacc.) Shoemaker (net blotch) on barley;
Phaeosphaeria nodorum (E. Müll.) Hedjar. (glume blotch) on
wheat; Magnaporthe grisea (T.T. Hebert) M.E. Barr(rice blast)
on rice.
The intrinsic antifungal activity of the compounds was tested in
liquid culture assays. Mycelial fragments prepared from a fresh
liquid culture (Pythium ultimum Trow; Rhizoctonia solani
Kühn) or conidia of the fungus from cryogenic storage (B.
cinerea; P. nodorum; P. grisea; Fusarium culmorum (Wm. G.
Sm.) Sacc.) were directly mixed into PDB potato dextrose
broth. 10 µL test solution in DMSO (2%) of different concen-
tration of 7 was placed into microtiter plates (96-well format)
and the nutrient broth (90 µL) containing the fungal cells was
added. The test plates were incubated at 24 °C and percent inhi-
bition of fungal growth was determined photometrically after
48 h (P. ultimum; F. culmorum; R. solani) or 72 h (B. cinerea;
P. nodorum; P. grisea) in relation to the non-treated control.
Supporting Information
Supporting Information File 1
NMR and MS spectra of myxocoumarin A (7) and B (9).
In-depth discussion and analysis of chemical shifts for the
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